Counting drugs to understand the disease: The case of measuring the diabetes epidemic

Table 4 Trend estimates for incidence, prevalence, and mortality with respect to treatment with anti-diabetic agents

Run-in	Treatment	Gender	Prevalence		Incidence		Mortality among treated		Relative Mortality
One year	All anti-diabetic	F	1.036	1.032, 1.040	1.045	1.035, 1.055	0.973	0.959, 0.987	0.991	0.986, 0.995
		M	1.044	1.040, 1.048	1.045	1.036, 1.054	0.974	0.961, 0.987	0.977	0.973, 0.982
	Insulin	F	1.036	1.030, 1.043	1.048	1.033, 1.064	0.977	0.955, 1.000	0.990	0.986, 0.994
		M	1.045	1.039, 1.050	1.067	1.053, 1.082	1.000	0.976, 1.023	0.977	0.973, 0.981
	Oral antidiab.	F	1.045	1.039, 1.051	1.052	1.042, 1.059	0.969	0.953, 0.986	0.992	0.987, 0.996
		M	1.052	1.046, 1.058	1.049	1.040, 1.058	0.959	0.943, 0.974	0.979	0.975, 0.984
Two year	All anti-diabetic	F	1.035	1.031, 1.039	1.048	1.038, 1.058	0.972	0.959, 0.986	0.990	0.986, 0.995
		M	1.045	1.040, 1.049	1.045	1.035, 1.054	0.978	0.965, 0.991	0.978	0.974, 0.982
	Insulin	F	1.034	1.028, 1.040	1.049	1.033, 1.065	0.970	0.949, 0.992	0.990	0.986, 0.994
		M	1.045	1.040, 1.051	1.065	1.050, 1.080	1.005	0.983, 1.028	0.977	0.973, 0.982
	Oral antidiab.	F	1.043	1.037, 1.049	1.055	1.045, 1.066	0.970	0.954, 0.987	0.991	0.987, 0.995
		M	1.052	1.046, 1.058	1.050	1.040, 1.060	0.964	0.949, 0.979	0.980	0.976, 0.984
Variable	All anti-diabetic	F	1.046	1.042, 1.050	1.032	1.023, 1.041	0.974	0.962, 0.985	0.991	0.987, 0.995
		M	1.053	1.049, 1.057	1.028	1.020, 1.036	0.973	0.962, 0.984	0.979	0.975, 0.982

Estimated age-adjusted, annual trends with 95%-confidence intervals for different categories of anti-diabetic drugs and with different lengths of run-in periods, Fyn County, Denmark, 1992–2003. For prevalence the trend estimate is given as an odds-ratio based on logistic regression, whereas the remaining estimates are rate-ratios based on Poisson regression. The start of the study period depends on the length of run-in period used.

ISSN: 1478-7954